Goldman Sachs’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-17,930
| Closed | -$193K | – | 5273 |
|
|
2025
Q1 | $193K | Sell |
17,930
-13,436
| -43% | -$145K | ﹤0.01% | 4687 |
|
|
2024
Q4 | $401K | Sell |
31,366
-10,250
| -25% | -$131K | ﹤0.01% | 4399 |
|
|
2024
Q3 | $1.15M | Buy |
41,616
+24,165
| +138% | +$667K | ﹤0.01% | 3677 |
|
|
2024
Q2 | $506K | Sell |
17,451
-3,833
| -18% | -$111K | ﹤0.01% | 3954 |
|
|
2024
Q1 | $949K | Sell |
21,284
-10,101
| -32% | -$450K | ﹤0.01% | 3653 |
|
|
2023
Q4 | $1.22M | Buy |
31,385
+4,504
| +17% | +$175K | ﹤0.01% | 3513 |
|
|
2023
Q3 | $790K | Sell |
26,881
-5,920
| -18% | -$174K | ﹤0.01% | 3657 |
|
|
2023
Q2 | $2.09M | Buy |
32,801
+5,024
| +18% | +$320K | ﹤0.01% | 3181 |
|
|
2023
Q1 | $1.31M | Sell |
27,777
-32,852
| -54% | -$1.55M | ﹤0.01% | 3489 |
|
|
2022
Q4 | $4.21M | Buy |
60,629
+41,368
| +215% | +$2.87M | ﹤0.01% | 2750 |
|
|
2022
Q3 | $2.82M | Buy |
19,261
+9,191
| +91% | +$1.35M | ﹤0.01% | 3092 |
|
|
2022
Q2 | $1.31M | Buy |
10,070
+752
| +8% | +$98.1K | ﹤0.01% | 3759 |
|
|
2022
Q1 | $941K | Buy |
9,318
+4,112
| +79% | +$415K | ﹤0.01% | 4146 |
|
|
2021
Q4 | $806K | Buy |
+5,206
| New | +$806K | ﹤0.01% | 4198 |
|
|
2021
Q3 | – | Sell |
-10,102
| Closed | -$3.28M | – | 5457 |
|
|
2021
Q2 | $3.28M | Buy |
+10,102
| New | +$3.28M | ﹤0.01% | 3109 |
|